TargetMRD

Cancer Can Be Kept in Check

Tumor Informed + Tumor Agnostic Molecular Residual Disease (MRD) Monitoring

The Importance of MRD Monitoring

Molecular Residual Disease monitoring plays a crucial role in the management of cancer. By detecting molecular residual disease, healthcare providers can make informed decisions about treatment adjustments, surveillance strategies, and early interventions, ultimately improving patient outcomes.

Target-MRD is the only minimal residual disease/molecular residual disease (MRD) detection assay to implement personalized tumor-informed and tumor-agnostic MRD detection and profiling.

Dual Approach - Target MRD

Tumor-Informed

Our tumor-informed testing analyzes specific genetic alterations unique to a patient’s tumor , providing personalized monitoring for disease recurrence. This tailored approach allows for precise tracking of residual disease and treatment efficacy.

Tumor-Agnostic

Our tumor-agnostic testing utilizes broad genomic profiling to identify common molecular markers across various cancers. This method is ideal for patients without a specific tumor profile, ensuring that everyone has access to critical insights into their disease status.

Target MRD Helps

Early Detection
of Relapse

MRD enables the detection of residual cancer cells at the molecular level before clinical or radiological relapse, allowing for earlier intervention and potentially better outcomes.

Tailored Treatment Decisions

MRD status informs personalized treatment decisions, helping clinicians decide whether to escalate, de-escalate, or discontinue treatment, depending on the presence of molecular disease.

Prognostic
Indicator

Detecting MRD provides valuable prognostic information, as patients with undetectable MRD often show improved outcomes, while those with detectable MRD are at higher risk of recurrence.

Guide to Post-Treatment Surveillance

MRD detection allows for ongoing monitoring in patients who are in remission, enabling dynamic adjustments of treatment and earlier detection of recurrence than traditional surveillance methods.

Advantages and Process - Target MRD

Robust Sensitivity:

Combination of Tumor-Informed and Tumor-Agnostic MRD.

Synergy of Technologies:

Utilising the two most advanced MRD technologies; NGS and ddPCR for accurate MRD detection.

Robust Specificity:

Paired gDNA analysis to rule out CHIP.

Step 1

Tissue Collection

FFPE block with sufficient  tumor content.

Step 2

Blood Collection

30 ml Blood in Streck Tubes.

Step 3

Analysis

Tumor tissue sequencing

Paired gDNA analaysis

Tumor informed ddPCR profiling

Tumor agnostic NGS profiling

Step 4

Reporting

Simplified reporting of MRD status incorporating findings of dual nature.

Contact Us

Whatsapp

India     |    Worldwide

(Messages Only)

500 EastRidge, Perimeter Park,
Morrisville, Raleigh,
North Carolina 27560. USA

10 Medawar Road,
The Surrey Research Park, Guildford,
Surrey, GU2 7AE, United Kingdom

Lessingweg1,
Bayreuth 95447,
Germany
F-8, D Road, Ambad,
Nasik, Maharashtra.
India

Accreditation*

To see our NABL-accredited scope, please follow the links for NABL accredited Scope.

*India Lab